Navigation Links
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
Date:2/27/2012

SAN DIEGO, Feb. 27, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) will report fourth quarter 2011 and fiscal year 2011 financial results and provide a business overview, including DIFICID® sales, commercialization and development, after the NASDAQ Global Market closes on March 7th.  The Company will host a conference call the same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO )

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the "Investors" section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call. 

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736
Dwalsey@optimerpharma.com

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005
Jason@canalecomm.com

 

 

 


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest ... is the first of its kind in the ... tattoos through advanced laser treatment. The physician-owned and ... Suncoast by storm with its revitalizing ... and advanced multi-wavelength Astanza Trinity technology. ...
(Date:2/5/2016)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s largest ... dental, animal health and medical practitioners, announced today that ... majority ownership interest in Dental Cremer S.A., a distributor ... . --> ... dental distribution business of Cremer S.A. With 2015 sales ...
(Date:2/4/2016)... IRVINE, Calif. , Feb. 4, 2016  Edwards ... in patient-focused innovations for structural heart disease and critical ... an accelerated share repurchase (ASR) agreement with Morgan Stanley ... common stock.  This repurchase is part of the Company,s ... of the Company,s common stock.  ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of the day ... feature of patients with eating disorders is significant self-criticism, and consequently these patients experience ... are regarded as maladaptive means for coping with this unease, but also leads to ...
(Date:2/5/2016)... ... 05, 2016 , ... California Mobile Kitchens , a ... their latest mobile kitchen model, featuring customizable stainless steel interiors and a new, ... for use anywhere in the U.S. Many of their units can be seen ...
(Date:2/5/2016)... ... ... Calls Blacklist has just been updated by mobile app developer Vlad Lee. ... fixed known bugs within the app. Calls Blacklist allows its users to only have ... of their device’s battery power or memory. It provides a powerful call blocker that ...
(Date:2/5/2016)... ... February 05, 2016 , ... –This week, Atascadero water heater ... having a tankless water heater. To view the report, click here or ... tankless. While each has their pros and cons, the type chosen is almost entirely ...
(Date:2/5/2016)... ... ... is tired of trying to cram belongings into spare space that just isn’t there, a ... but before hastily spending money on a unit, take these tips into consideration. , Self-storage ... is often not told when utilizing these services are some tips on how to use ...
Breaking Medicine News(10 mins):